INOPlusBellerophon Starts INOpulse Treatment in Coronavirus Patients

Published 1 April 2020

Bellerophon Therapeutics has treated the first Covid-19 patient with its INOpulse at the University of Miami School of Medicine in the US.
This comes after the company received emergency expanded access from the U.S. Food and Drug Administration (FDA) for the inhaled nitric oxide system (iNO).
Clinical Trials Arena reports that NO is a naturally produced molecule that plays a key role in the immune response against pathogens and infections.
In-vitro studies found that NO blocks the replication of severe acute respiratory syndrome-related coronavirus (SARS-CoV) and improves the survival of infected cells.